Piramal Pharma Limited — Updates, 14-05-2025: Press Release

Piramal Pharma has announced a board meeting. FY revenue rose 12%, driven by a 15% jump in CDMO revenues with on-patent manufacturing hitting $179mn. EBITDA grew 15% on cost efficiencies, maintaining a 17% margin. Consumer Healthcare sales surpassed ₹1,000 Cr, up 11%, boosted by power brands and 39% e-commerce growth. Complex Hospital Generics revenues increased 8%, though EBITDA margin dipped due to capacity expansion. Net Debt/EBITDA improved significantly to 2.7x from 5.6x, supported by strong operational performance and solid ESG credentials.